31 August 2017Big Pharma

Video interview: Predicting Brexit’s life sciences impact

The practical implications of Brexit, including on the Unified Patent Court (UPC), were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

Hosted by LSIPR in Boston earlier this year, the event featured a host of roundtables, one of which covered the impact of Brexit for companies in the UK and Europe.

Zoë Butler, partner at Powell Gilbert, who chaired the discussion, explains that the participants were “trying to predict what might happen”, for example whether the UPC will go ahead and whether UK will be part of it.

To find out more, you can watch the video below.


More on this story

Big Pharma
25 August 2017   With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.
Americas
23 August 2017   The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More on this story

Big Pharma
25 August 2017   With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.
Americas
23 August 2017   The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.